Silence Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLNCF research report →
Companywww.silence-therapeutics.com
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.
- CEO
- Iain Gladstone Ross
- IPO
- 2012
- Employees
- 116
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $150.21M
- P/E
- -3.93
- P/S
- 351.60
- P/B
- 5.97
- EV/EBITDA
- -4.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 66.86%
- Op Margin
- -9267.51%
- Net Margin
- -8948.43%
- ROE
- -107.19%
- ROIC
- -74.16%
Growth & Income
- Revenue
- $559.00K · -98.71%
- Net Income
- $-88,612,000 · -95.57%
- EPS
- $-0.63 · -90.91%
- Op Income
- $-82,290,000
- FCF YoY
- 8.14%
Performance & Tape
- 52W High
- $2.63
- 52W Low
- $0.97
- 50D MA
- $2.12
- 200D MA
- $1.77
- Beta
- 0.85
- Avg Volume
- 181
Get TickerSpark's AI analysis on SLNCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SLNCF Coverage
We haven't published any research on SLNCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLNCF Report →